NeoTYPE Cancer Profiles

NeoTYPE™ Cancer Profiles are multi-method test panels, custom-designed for a specific tumor type, that identify the genetic changes most significant to therapy decisions, prognosis, and clinical research. Read more.


123
Methodology Test Name Test Description Results per page:
NeoTYPE Profiles NeoTYPE™ AML Favorable-Risk Profile This test is performed by sequencing of select exons of the genes FLT3 and KIT. Test orders include summary interpretation of all results together. Individual genes from a validated list of myeloid genes can be added-on. In addition, the genes listed above can be ordered separately and will be reported individually without summary interpretation.
NeoTYPE Profiles NeoTYPE™ AML Prognostic Profile

This test is performed by sequencing of select exons of the genes listed. ASXL1, BCOR, BRAF, CEBPA, CSF3R, DNMT3A, ETV6, EZH2, FLT3, HRAS, IDH1, IDH2, JAK2 V617F, JAK2 Exon 12+14, KIT, KRAS, MLL, NPM1, NRAS, PDGFRA, PHF6, PTPN11, RUNX1, SETBP1, STAG2, TET2, TP53 and WT1. Individual genes from a validated list of myeloid genes can be added on. Test orders include summary interpretation of all results together. Any tests may be ordered separately; these will be reported individually without summary interpretation. The AML Prognostic Profile may also be ordered as reflex after intermediate cytogenetics in the AML Reflex Panel (see separate AML Reflex Panel listing).

For patients with therapy-related AML, AML that evolved from MDS, and AML with myelodysplasia, we recommend instead the NeoTYPE MDS/CMML Profile.

NeoTYPE Profiles NeoTYPE™ Brain Tumor Profile This test is performed by the sequencing of select exons of the genes listed unless another method is noted. AKT1, ATRX, BRAF, CTNNB1, EGFR, ERBB2, ERBB4, FGFR1, FGFR2, FGFR3, IDH1, IDH2, MET, MGMT Promoter Methylation Analysis, PIK3CA, PTEN, SMAD4, SMO, SRC, TP53, 1p/19q Deletion FISH, BRAF FISH, MET FISH, MYCN FISH, PTEN FISH, and PD-L1 IHC. Individual genes from a validated list of solid tumor genes can be added on. Test orders include summary interpretation of all results together. FISH / Flow components of NeoTYPE Profiles may be ordered as "Tech-Only" by pathology clients who wish to perform the professional component. Any tests may be ordered separately; these will be reported individually without summary interpretation. 
NeoTYPE Profiles NeoTYPE™ Breast Tumor Profile This test is performed by the sequencing of select exons of the genes listed unless another method is noted. AKT1, BRAF, BRCA1, BRCA2, CTNNB1, EGFR, ERBB2, ERBB4, FGFR1, FGFR2, FGFR3, HRAS, KIT, KRAS, MET, NRAS, PIK3CA, PTEN, SMAD4, SMO, SRC, TP53, HER2 FISH, MET FISH, PTEN FISH and PD-L1 IHC. Individual genes from a validated list of solid tumor genes can be added-on. Test orders include summary interpretation of all results together.  FISH / Flow components of NeoTYPE Profiles may be ordered as “Tech-Only” by pathology clients who wish to perform the professional component. Any tests may be ordered separately; these will be reported individually without summary interpretation. Note - Samples with equivocal HER2 FISH results will be reflexed to the Equivocal Breast FISH Panel. BRCA1/2 testing will be performed unless opted out.
NeoTYPE Profiles NeoTYPE™ Cancer Exome Profile The NeoTYPE Cancer Exome Profile is performed by massive parallel sequencing of the coding regions in 4813 different cancer related genes. Test orders include summary interpretation of all results together.
NeoTYPE Profiles NeoTYPE™ Cervical Tumor Profile This test is performed by the sequencing of select exons of the genes listed unless another method is noted. AKT1, BRAF, CTNNB1, EGFR, ERBB2, ERBB4, FGFR1, FGFR2, FGFR3, HRAS, JAK3, KRAS, MET, NOTCH1, NRAS, PDGFRA, PIK3CA, PTEN, SMAD4, SMO, SRC, TP53, MET FISH, PTEN FISH and PD-L1 IHC. Individual genes from a validated list of solid tumor genes can be added-on. Test orders include summary interpretation of all results together. FISH / Flow components of NeoTYPE Profiles may be ordered as "Tech-Only" by pathology clients who wish to perform the professional component. Any tests may be ordered separately; these will be reported individually without summary interpretation.
NeoTYPE Profiles NeoTYPE™ CLL Prognostic Profile This test is performed by the sequencing of select exons of the genes listed, plus the CLL FISH Panel and ZAP-70 flow cytometry as noted. IgVH Mutation, MYD88, NOTCH1, SF3B1, TP53. Individual genes from a validated list of myeloid genes can be added-on. Test orders include summary interpretation of all results together. FISH / Flow components of NeoTYPE Profiles may be ordered as "Tech-Only" by pathology clients who wish to perform the professional component. Any tests may be ordered separately; these will be reported individually without summary interpretation.
NeoTYPE Profiles NeoTYPE™ Colorectal Tumor Profile This test is performed by the sequencing of select exons of the genes listed unless another method is noted. AKT1, APC, BRAF, EGFR, ERBB2, ERBB4, FGFR1, FGFR2, FGFR3, HRAS, JAK3, KIT, KRAS, MET, Microsatellite Instability (MSI), MLH1 Promoter Methylation, NOTCH1, NRAS, PDGFRA, PIK3CA, PTEN, SMO, SRC, TP53, MET FISH, PTEN FISH and PD-L1 IHC. Individual genes from the 48 gene Solid Tumor panel can be added on. Test orders include summary interpretation of all results together. FISH / Flow components of NeoTYPE Profiles may be ordered as "Tech-Only" by pathology clients who wish to perform the professional component. Any tests may be ordered separately; these will be reported individually without summary interpretation.
NeoTYPE Profiles NeoTYPE™ CUP Consult A full morphologic/IHC consult for cancer of unknown primary (CUP) is performed by NeoGenomics’ pathologists with concurrent multi-method NeoTYPE™ Discovery Profile testing and comprehensive, integrated final reporting on cumulative results.  The Discovery Profile includes molecular analysis of 315 genes, FISH analysis of 9 amplifications or rearrangements, and PD-L1 IHC; details of this test are available here.  Reports of component tests are issued as soon as completed, beginning at approximately day 3 of the testing period through the final summary report issued at approximately day 22.
NeoTYPE Profiles NeoTYPE™ Discovery Profile for Solid Tumors This test is performed by the sequencing of select exons of the genes listed unless another method is noted.  ABL1, ABL2, ACVR1B, AKT1, AKT2, AKT3, ALK, AMER1 (FAM123B), APC, AR, ARAF, ARFRP1, ARID1A, ARID1B, ARID2, ASXL1, ATM, ATR, ATRX, AURKA, AURKB, AXIN1, AXL, BAP1, BARD1, BCL2, BCL2L1, BCL2L2, BCL6, BCOR, BCORL1, BLM, BRAF, BRCA1, BRCA2, BRD4, BRIP1, BTG1, BTK, C11orf30, CARD11, CBFB, CBL, CCND1, CCND2, CCND3, CCNE1, CD274, CD79A, CD79B, CDC73, CDH1, CDK12, CDK4, CDK6, CDK8, CDKN1A, CDKN1B, CDKN2A, CDKN2B, CDKN2C, CEBPA, CHD2, CHD4, CHEK1, CHEK2, CIC, CREBBP, CRKL, CRLF2, CSF1R, CTCF, CTNNA1, CTNNB1, CUL3, CYLD, DAXX, DDR2, DICER1, DNMT3A, DOT1L, EGFR, EP300, EPHA3, EPHA5, EPHA7, EPHB1, ERBB2, ERBB3, ERBB4, ERG, ERRFI1, ESR1, EZH2, FAM46C, FANCA, FANCC, FANCD2, FANCE, FANCF, FANCG, FANCL, FAS, FAT1, FBXW7, FGF10, FGF14, FGF19, FGF23, FGF3, FGF4, FGF6, FGFR1, FGFR2, FGFR3, FGFR4, FH, FLCN, FLT1, FLT3, FLT4, FOXL2, FOXP1, FRS2, FUBP1, GABRA6, GATA1, GATA2, GATA3, GATA4, GATA6, GID4 (C17orf39), GLI1, GNA11, GNA13, GNAQ, GNAS, GPR124, GRIN2A, GRM3, GSK3B, H3F3A, HGF, HNF1A, HRAS, HSD3B1, HSP90AA1, IDH1, IDH2, IGF1R, IGF2, IKBKE, IKZF1, IL7R, INHBA, INPP4B, IRF2, IRF4, IRS2, JAK1, JAK2, JAK3, JUN, KAT6A (MYST3), KDM5A, KDM5C, KDM6A, KDR, KEAP1, KEL, KIT, KLHL6, KMT2A (MLL), KMT2C (MLL3), KMT2D (MLL2), KRAS, LMO1, LRP1B, LYN, LZTR1, MAGI2, MAP2K1, MAP2K2, MAP2K4, MAP3K1, MCL1, MDM2, MDM4, MED12, MEF2B, MEN1, MET, MITF, MLH1, MPL, MRE11A, MSH2, MSH6, MTOR, MUTYH, MYC, MYCL (MYCL1), MYCN, MYD88, NF1, NF2, NFE2L2, NFKBIA, NKX2-1, NOTCH1, NOTCH2, NOTCH3, NPM1, NRAS, NSD1, NTRK1, NTRK2, NTRK3, NUP93, PAK3, PALB2, PARK2, PAX5, PBRM1, PDCD1LG2, PDGFRA, PDGFRB, PDK1, PIK3C2B, PIK3CA, PIK3CB, PIK3CG, PIK3R1, PIK3R2, PLCG2, PMS2, POLD1, POLE, PPP2R1A, PRDM1, PREX2, PRKAR1A, PRKCI, PRKDC, PRSS8, PTCH1, PTEN, PTPN11, QKI, RAC1, RAD50, RAD51, RAF1, RANBP2, RARA, RB1, RBM10, RET, RICTOR, RNF43, ROS1, RPTOR, RUNX1, RUNX1T1, SDHA, SDHB, SDHC, SDHD, SETD2, SF3B1, SLIT2, SMAD2, SMAD3, SMAD4, SMARCA4, SMARCB1, SMO, SNCAIP, SOCS1, SOX10, SOX2, SOX9, SPEN, SPOP, SPTA1, SRC, STAG2, STAT3, STAT4, STK11, SUFU, SYK, TAF1, TBX3, TERC, TERT (promoter only), TET2, TGFBR2, TNFAIP3, TNFRSF14, TOP1, TOP2A, TP53, TSC1, TSC2, TSHR, U2AF1, VEGFA, VHL, WISP3, WT1, XPO1, ZBTB2, ZNF217, ZNF703, ALK FISH, BRAF FISH, HER2 FISH, MET FISH, c-MYC FISH, PDGFRA FISH, PTEN FISH, RET RISH, ROS1 FISH and PD-L1 IHC. Test orders include summary interpretation of all results together. Note - Breast samples with equivocal HER2 FISH results will be reflexed to the Equivocal Breast FISH Panel.
123